Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma

Purpose SF1126 is a vascular-targeted pan-PI-3K inhibitor prodrug with antitumor and antiangiogenic activity and has completed phase I clinical trial in solid tumors and B-cell malignancies. In this study, we investigated the effect of SF1126 on hypoxic HIF-1α/HIF-2α stability as well as on antitumo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2015-03, Vol.75 (3), p.595-608
Hauptverfasser:	Joshi, Shweta, Singh, Alok R., Durden, Donald L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - pharmacology Animals Antineoplastic Agents - pharmacology Cancer Research Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Cell Line, Tumor Chromones - pharmacology Female Humans Hypoxia-Inducible Factor 1, alpha Subunit - drug effects Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Injections, Subcutaneous Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Medicine Medicine & Public Health Mice Mice, Nude Oligopeptides - pharmacology Oncology Original Article Pharmacology/Toxicology Phosphatidylinositol 3-Kinases - antagonists & inhibitors Prodrugs Von Hippel-Lindau Tumor Suppressor Protein - genetics Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!